Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome | Zendy

Sarah Hendrickx | Zendy; Eline Eberhardt | Zendy; Annelies Mondelaers | Zendy; Suman Rijal | Zendy; Narayan Raj Bhattarai | Zendy; JeanClaude Dujardin | Zendy; Peter Delputte | Zendy; Paul Cos | Zendy; Louis Maes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome

Author(s) -

Sarah Hendrickx,

Eline Eberhardt,

Annelies Mondelaers,

Suman Rijal,

Narayan Raj Bhattarai,

JeanClaude Dujardin,

Peter Delputte,

Paul Cos,

Louis Maes

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv237

Subject(s) - miltefosine , amastigote , leishmaniasis , leishmania donovani , biology , drug resistance , visceral leishmaniasis , medicine , leishmania , immunology , microbiology and biotechnology , parasite hosting , world wide web , computer science

Widespread antimony resistance in the Indian subcontinent has enforced a therapy shift in visceral leishmaniasis treatment primarily towards miltefosine and secondarily also towards paromomycin. In vitro selection of miltefosine resistance in Leishmania donovani turned out to be quite challenging. Although no increase in IC50 was detected in the standard intracellular amastigote susceptibility assay, promastigote back-transformation remained positive at high miltefosine concentrations, suggesting a more 'resistant' phenotype. This observation was explored in a large set of Nepalese clinical isolates from miltefosine cure and relapse patients to assess its predictive value for patient treatment outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research